Literature DB >> 19592665

Structure-activity relationship studies of fostriecin, cytostatin, and key analogs, with PP1, PP2A, PP5, and( beta12-beta13)-chimeras (PP1/PP2A and PP5/PP2A), provide further insight into the inhibitory actions of fostriecin family inhibitors.

Mark R Swingle1, Lauren Amable, Brian G Lawhorn, Suzanne B Buck, Christopher P Burke, Pukar Ratti, Kimberly L Fischer, Dale L Boger, Richard E Honkanen.   

Abstract

Fostriecin and cytostatin are structurally related natural inhibitors of serine/threonine phosphatases, with promising antitumor activity. The total synthesis of these antitumor agents has enabled the production of structural analogs, which are useful to explore the biological significance of features contained in the parent compounds. Here, the inhibitory activity of fostriecin, cytostatin, and 10 key structural analogs were tested in side-by-side phosphatase assays to further characterize their inhibitory activity against PP1c (Ser/Thr protein phosphatase 1 catalytic subunit), PP2Ac (Ser/Thr protein phosphatase 2A catalytic subunit), PP5c (Ser/Thr protein phosphatase 5 catalytic subunit), and chimeras of PP1 (Ser/Thr protein phosphatase 1) and PP5 (Ser/Thr protein phosphatase 5), in which key residues predicted for inhibitor contact with PP2A (Ser/Thr protein phosphatase 2A) were introduced into PP1 and PP5 using site-directed mutagenesis. The data confirm the importance of the C9-phosphate and C11-alcohol for general inhibition and further demonstrate the importance of a predicted C3 interaction with a unique cysteine (Cys(269)) in the beta12-beta13 loop of PP2A. The data also indicate that additional features beyond the unsaturated lactone contribute to inhibitory potency and selectivity. Notably, a derivative of fostriecin lacking the entire lactone subunit demonstrated marked potency and selectivity for PP2A, while having substantially reduced and similar activity against PP1 and PP1/PP2A- PP5/PP2A-chimeras that have greatly increased sensitivity to both fostriecin and cytostatin. This suggests that other features [e.g., the (Z,Z,E)-triene] also contribute to inhibitory selectivity. When considered together with previous data, these studies suggest that, despite the high structural conservation of the catalytic site in PP1, PP2A and PP5, the development of highly selective catalytic inhibitors should be feasible.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19592665      PMCID: PMC2766224          DOI: 10.1124/jpet.109.155630

Source DB:  PubMed          Journal:  J Pharmacol Exp Ther        ISSN: 0022-3565            Impact factor:   4.030


  33 in total

1.  Pharmacophore identification: the case of the ser/thr protein phosphatase inhibitors.

Authors:  David A Colby; A Richard Chamberlin
Journal:  Mini Rev Med Chem       Date:  2006-06       Impact factor: 3.862

2.  SODOCK: swarm optimization for highly flexible protein-ligand docking.

Authors:  Hung-Ming Chen; Bo-Fu Liu; Hui-Ling Huang; Shiow-Fen Hwang; Shinn-Ying Ho
Journal:  J Comput Chem       Date:  2007-01-30       Impact factor: 3.376

3.  Three-dimensional structure of the catalytic subunit of protein serine/threonine phosphatase-1.

Authors:  J Goldberg; H B Huang; Y G Kwon; P Greengard; A C Nairn; J Kuriyan
Journal:  Nature       Date:  1995-08-31       Impact factor: 49.962

4.  Total synthesis of fostriecin (CI-920).

Authors:  D L Boger; S Ichikawa; W Zhong
Journal:  J Am Chem Soc       Date:  2001-05-09       Impact factor: 15.419

5.  Total synthesis and biological evaluation of the protein phosphatase 2A inhibitor cytostatin and analogues.

Authors:  Laurent Bialy; Herbert Waldmann
Journal:  Chemistry       Date:  2004-06-07       Impact factor: 5.236

6.  Fundamental role of the fostriecin unsaturated lactone and implications for selective protein phosphatase inhibition.

Authors:  Suzanne B Buck; Christophe Hardouin; Satoshi Ichikawa; Danielle R Soenen; C-M Gauss; Inkyu Hwang; Mark R Swingle; Kathy M Bonness; Richard E Honkanen; Dale L Boger
Journal:  J Am Chem Soc       Date:  2003-12-24       Impact factor: 15.419

Review 7.  Fostriecin: chemistry and biology.

Authors:  D S Lewy; C-M Gauss; D R Soenen; D L Boger
Journal:  Curr Med Chem       Date:  2002-11       Impact factor: 4.530

8.  Structural basis for the catalytic activity of human serine/threonine protein phosphatase-5.

Authors:  Mark R Swingle; Richard E Honkanen; Ewa M Ciszak
Journal:  J Biol Chem       Date:  2004-05-23       Impact factor: 5.157

9.  Mutational analysis of the catalytic subunit of muscle protein phosphatase-1.

Authors:  J Zhang; Z Zhang; K Brew; E Y Lee
Journal:  Biochemistry       Date:  1996-05-21       Impact factor: 3.162

10.  Differential induction of apoptosis in B16 melanoma and EL-4 lymphoma cells by cytostatin and bactobolin.

Authors:  M Kawada; M Amemiya; M Ishizuka; T Takeuchi
Journal:  Jpn J Cancer Res       Date:  1999-02
View more
  19 in total

1.  Cytokines alter glucocorticoid receptor phosphorylation in airway cells: role of phosphatases.

Authors:  Belaid Bouazza; Kateryna Krytska; Manel Debba-Pavard; Yassine Amrani; Richard E Honkanen; Jennifer Tran; Omar Tliba
Journal:  Am J Respir Cell Mol Biol       Date:  2012-05-16       Impact factor: 6.914

Review 2.  Synthetic Strategies Employed for the Construction of Fostriecin and Related Natural Products.

Authors:  Barry M Trost; Joshua D Knopf; Cheyenne S Brindle
Journal:  Chem Rev       Date:  2016-12-08       Impact factor: 60.622

3.  The Antitumor Drug LB-100 Is a Catalytic Inhibitor of Protein Phosphatase 2A (PPP2CA) and 5 (PPP5C) Coordinating with the Active-Site Catalytic Metals in PPP5C.

Authors:  Brandon M D'Arcy; Mark R Swingle; Cinta M Papke; Kevin A Abney; Erin S Bouska; Aishwarya Prakash; Richard E Honkanen
Journal:  Mol Cancer Ther       Date:  2019-01-24       Impact factor: 6.261

Review 4.  Regulation of the Hippo pathway and implications for anticancer drug development.

Authors:  Hyun Woo Park; Kun-Liang Guan
Journal:  Trends Pharmacol Sci       Date:  2013-09-16       Impact factor: 14.819

5.  Disruption of serine/threonine protein phosphatase 5 (PP5:PPP5c) in mice reveals a novel role for PP5 in the regulation of ultraviolet light-induced phosphorylation of serine/threonine protein kinase Chk1 (CHEK1).

Authors:  Lauren Amable; Nina Grankvist; Jason W Largen; Henrik Ortsäter; Åke Sjöholm; Richard E Honkanen
Journal:  J Biol Chem       Date:  2011-09-15       Impact factor: 5.157

6.  Development and validation of a robust and sensitive assay for the discovery of selective inhibitors for serine/threonine protein phosphatases PP1α (PPP1C) and PP5 (PPP5C).

Authors:  Mark R Swingle; Richard E Honkanen
Journal:  Assay Drug Dev Technol       Date:  2014-10       Impact factor: 1.738

7.  Suppression of Ser/Thr phosphatase 4 (PP4C/PPP4C) mimics a novel post-mitotic action of fostriecin, producing mitotic slippage followed by tetraploid cell death.

Authors:  Benjamin Theobald; Kathy Bonness; Alla Musiyenko; Joel F Andrews; Gudrun Urban; Xizhong Huang; Nicholas M Dean; Richard E Honkanen
Journal:  Mol Cancer Res       Date:  2013-05-13       Impact factor: 5.852

8.  PP1:Tautomycetin Complex Reveals a Path toward the Development of PP1-Specific Inhibitors.

Authors:  Meng S Choy; Mark Swingle; Brandon D'Arcy; Kevin Abney; Scott F Rusin; Arminja N Kettenbach; Rebecca Page; Richard E Honkanen; Wolfgang Peti
Journal:  J Am Chem Soc       Date:  2017-11-28       Impact factor: 15.419

Review 9.  Viewing serine/threonine protein phosphatases through the eyes of drug designers.

Authors:  Mengmeng Zhang; S D Yogesha; Joshua E Mayfield; Gordon N Gill; Yan Zhang
Journal:  FEBS J       Date:  2013-09-05       Impact factor: 5.542

10.  Crystal structures and mutagenesis of PPP-family ser/thr protein phosphatases elucidate the selectivity of cantharidin and novel norcantharidin-based inhibitors of PP5C.

Authors:  Debasish Chattopadhyay; Mark R Swingle; Edward A Salter; Eric Wood; Brandon D'Arcy; Catherine Zivanov; Kevin Abney; Alla Musiyenko; Scott F Rusin; Arminja Kettenbach; Larry Yet; Chad E Schroeder; Jennifer E Golden; Wade H Dunham; Anne-Claude Gingras; Surajit Banerjee; David Forbes; Andrzej Wierzbicki; Richard E Honkanen
Journal:  Biochem Pharmacol       Date:  2016-03-23       Impact factor: 5.858

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.